Investigate the effect of AZD1656 on the pharmacokinetics of Sitagliptin in patients with Type 2 Diabetes Mellitus

Study identifier:D1020C00032

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomised, Open, Phase I Study in Patients with Type 2 Diabetes Mellitus Treated with Metformin to Evaluate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin and Vice Versa

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 1

Healthy volunteers

Study drug

AZD1656, Sitagliptin

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 01 Mar 2010

Primary Completion Date: 01 May 2010

Study Completion Date: 01 May 2010

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Neuss, Germany

Arms	Assigned Interventions
Experimental: 1 AZD1656, day 1-5, AZD1656 + Sitagliptin day 6-10, Sitagliptin day 11-15.	Drug: AZD1656 Oral tablet bd, Drug: Sitagliptin Oral tablet od Other Name: Januvia
Experimental: 2 Sitagliptin day 1-5, AZD1656 + Sitagliptin day 6-10, AZD1656 day 11-15.	Drug: AZD1656 Oral tablet bd, Drug: Sitagliptin Oral tablet od Other Name: Januvia

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1710&filename=CSR-D1020C00032.pdf
Download
CSR-D1020C00032.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

Quintiles Uppsala

+ 46 184311175

Investigators

Principal Investigator

Stanko Skrtic

AstraZeneca Molndal Sweden